martedì 19 maggio 2020

Atezolizumab Combined with Bevacizumab in Unresetable HCC - Results of IMbrave150 show better overall and progression-free survival with combined treatment in patients with unresectable hepatocellular carcinoma

Fonte: ESMO European Society for Medical Oncology

Link all'articolo completo